JP2013510164A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510164A5
JP2013510164A5 JP2012537994A JP2012537994A JP2013510164A5 JP 2013510164 A5 JP2013510164 A5 JP 2013510164A5 JP 2012537994 A JP2012537994 A JP 2012537994A JP 2012537994 A JP2012537994 A JP 2012537994A JP 2013510164 A5 JP2013510164 A5 JP 2013510164A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding portion
amino acid
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012537994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510164A (ja
JP6007420B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/055489 external-priority patent/WO2011056997A1/en
Publication of JP2013510164A publication Critical patent/JP2013510164A/ja
Publication of JP2013510164A5 publication Critical patent/JP2013510164A5/ja
Application granted granted Critical
Publication of JP6007420B2 publication Critical patent/JP6007420B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012537994A 2009-11-04 2010-11-04 親和性成熟に基づく抗体最適化方法 Expired - Fee Related JP6007420B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28061809P 2009-11-04 2009-11-04
US61/280,618 2009-11-04
US39567010P 2010-05-13 2010-05-13
US61/395,670 2010-05-13
PCT/US2010/055489 WO2011056997A1 (en) 2009-11-04 2010-11-04 Methods for affinity maturation-based antibody optimization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016160082A Division JP2017031153A (ja) 2009-11-04 2016-08-17 親和性成熟に基づく抗体最適化方法

Publications (3)

Publication Number Publication Date
JP2013510164A JP2013510164A (ja) 2013-03-21
JP2013510164A5 true JP2013510164A5 (enExample) 2016-08-04
JP6007420B2 JP6007420B2 (ja) 2016-10-12

Family

ID=43431029

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012537994A Expired - Fee Related JP6007420B2 (ja) 2009-11-04 2010-11-04 親和性成熟に基づく抗体最適化方法
JP2016160082A Pending JP2017031153A (ja) 2009-11-04 2016-08-17 親和性成熟に基づく抗体最適化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016160082A Pending JP2017031153A (ja) 2009-11-04 2016-08-17 親和性成熟に基づく抗体最適化方法

Country Status (6)

Country Link
US (2) US20120316071A1 (enExample)
EP (1) EP2496600A1 (enExample)
JP (2) JP6007420B2 (enExample)
AU (2) AU2010315101B2 (enExample)
CA (1) CA2780221A1 (enExample)
WO (1) WO2011056997A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
US9150651B2 (en) * 2011-01-06 2015-10-06 Glaxo Group Limited Single variable domain immunoglobulins that bind TGF-beta receptor II
WO2013048883A2 (en) 2011-09-30 2013-04-04 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
HK1201855A1 (en) 2011-11-01 2015-09-11 Bionomics, Inc. Antibodies and methods of treating cancer
CN107353342B (zh) * 2011-12-05 2021-08-10 X 博迪生物科学公司 PDGF受体β结合多肽
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
MX374811B (es) * 2013-03-15 2025-03-06 Ac Immune Sa Anticuerpos anti-tau y métodos de uso.
US10141930B2 (en) 2013-06-04 2018-11-27 Nvidia Corporation Three state latch
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
SMT202100473T1 (it) * 2013-11-06 2021-09-14 Janssen Biotech Inc Anticorpi anti-ccl17
KR102127408B1 (ko) * 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
GB201403775D0 (en) * 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2944649C (en) 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
CN107531785B (zh) 2014-10-07 2021-06-29 卡德门企业有限公司 人抗-vegfr-2/kdr抗体
WO2016100615A2 (en) * 2014-12-18 2016-06-23 The University Of Chicago Methods and composition for neutralization of influenza
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
TW201639891A (zh) * 2015-03-10 2016-11-16 索倫多醫療公司 結合ｐｓｍａ之抗體治療劑
PL3283524T3 (pl) 2015-04-17 2023-06-12 Amgen Research (Munich) Gmbh Konstrukty biswoistego przeciwciała dla cdh3 i cd3
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
JP6979976B2 (ja) * 2016-03-10 2021-12-15 ヴィエラ バイオ，インコーポレーテッド Ｉｌｔ７結合分子及びその使用方法
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
EA201892716A1 (ru) * 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
CN109804234B (zh) * 2016-08-18 2023-03-17 皮瑞克生物医学有限公司 血液单元测试试剂盒
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018162944A1 (en) * 2017-03-04 2018-09-13 Shenzhen Runshin Bioscience Recombinant antibodies to programmed death 1 (pd-1) and uses therefor
CA3055790A1 (en) * 2017-04-07 2018-10-11 Igm Biosciences, Inc. Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
AU2019206207B2 (en) * 2018-01-15 2025-04-10 Stichting Sanquin Bloedvoorziening Factor H potentiating antibodies and uses thereof
EP3768723A4 (en) * 2018-03-23 2021-12-29 Board of Regents, The University of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
JP7631296B2 (ja) 2019-07-17 2025-02-18 ジェミニ・セラピューティクス・サブ・インコーポレイテッド Ｈ因子増強性抗体及びその使用
US11634501B2 (en) 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
MX2022002239A (es) * 2019-08-23 2022-03-22 Igm Biosciences Inc Glicovariantes de igm.
MX2022005983A (es) 2019-11-18 2022-09-07 Janssen Biotech Inc Receptores del antígeno quimérico anti-cd79, células car-t, y usos de estos.
EP4076526A4 (en) 2019-12-17 2024-07-03 The Board Of Regents Of The University Of Texas System Novel ddr1 antibodies and uses thereof
HUE062777T2 (hu) 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
WO2021203013A2 (en) 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
TWI868379B (zh) * 2020-07-09 2025-01-01 大陸商北京凱因科技股份有限公司 結合ｂ型肝炎病毒表面抗原的抗體及其應用
MX2023004023A (es) * 2020-10-09 2023-07-07 Hospital For Sick Children Polipéptidos que eligen como objetivo a sars-cov-2 y composiciones y métodos relacionados.
CN113032332B (zh) * 2021-02-26 2024-07-16 广东核电合营有限公司 标牌数据处理方法、装置、计算机设备和存储介质
EP4370545A1 (en) * 2021-07-12 2024-05-22 Genentech, Inc. Structures for reducing antibody-lipase binding
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
JP2023042974A (ja) * 2021-09-15 2023-03-28 シスメックス株式会社 抗サイトカイン抗体の抗原に対する親和性を向上させる方法、抗サイトカイン抗体の製造方法及び抗サイトカイン抗体
IL312003A (en) * 2021-10-15 2024-06-01 Astrazeneca Ab Chimeric ANTI-STEAP2 receptors and their uses
WO2023192976A1 (en) 2022-04-01 2023-10-05 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
CN114775065B (zh) * 2022-04-22 2026-01-06 武汉华美生物工程有限公司 一种半合成纳米抗体库构建方法和纳米抗体库

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE69127749T2 (de) 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5545142A (en) 1991-10-18 1996-08-13 Ethicon, Inc. Seal members for surgical trocars
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US20020102613A1 (en) 1999-05-18 2002-08-01 Hoogenboom Hendricus Renerus Jacobus Mattheus Novel Fab fragment libraries and methods for their use
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
PT1292335E (pt) 2000-06-23 2007-08-13 Bayer Schering Pharma Ag Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii)
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
FR2816319B1 (fr) 2000-11-08 2004-09-03 Millegen Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20030022240A1 (en) 2001-04-17 2003-01-30 Peizhi Luo Generation and affinity maturation of antibody library in silico
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2005023993A2 (en) 2003-09-09 2005-03-17 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
AU2006210660B2 (en) 2005-02-01 2011-12-01 Morphosys Ag Libraries and methods for isolating antibodies
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
US8716195B2 (en) 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
US20090318308A1 (en) 2006-05-30 2009-12-24 Millegen Highly diversified antibody libraries
US9102711B2 (en) * 2007-12-31 2015-08-11 Xoma Technology Ltd. Methods and materials for targeted mutagenesis
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof

Similar Documents

Publication Publication Date Title
KR102290949B1 (ko) 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리
JP6267689B2 (ja) 多重特異性モノクローナル抗体
Könning et al. Beyond antibody engineering: directed evolution of alternative binding scaffolds and enzymes using yeast surface display
US10093740B2 (en) Bispecific HER2 ligands for cancer therapy
AU2006204459B2 (en) Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
JP5508002B2 (ja) 免疫グロブリンのエンジニアリング方法
EP2719706A1 (en) Bispecific HER2 ligands for cancer therapy
JP2011507519A (ja) ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
NO325823B1 (no) Humaniserte antistoffer, fremgangsmate for a fremstille humaniserte antistoffer og anvendelsen av slike.
JP2026065087A (ja) 操作されたｃｄ２５ポリペプチドおよびその使用
EP2496600A1 (en) Methods for affinity maturation-based antibody optimization
JP2021500873A (ja) システイン操作された抗原結合分子
US20060275811A1 (en) Method for producing target substance capturing protein and method for selecting component materials thereof
EP2619578B1 (en) Method of analyzing binding interactions
TW202028239A (zh) 針對可溶性bcma之抗體
JP2020534796A (ja) エピトープ翻訳後修飾状態に特異的な抗体の開発方法及び開発のための組成物
CA3011827C (en) A method of generating a synthetic antibody library, said library and application(s) thereof
US20110245100A1 (en) Generation of antibodies to an epitope of interest
US20130109586A1 (en) Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acid
KR20220026869A (ko) 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리
JP2025510539A5 (enExample)
KR20250170468A (ko) 신규의 인간 가변 도메인 스캐폴드 및 이를 기반으로 한 단일 도메인 항체 라이브러리
Vellalore Maruthachalam NEXT-GENERATION SEQUENCING AND MOTIF GRAFTING APPLICATIONS IN SYNTHETIC ANTIBODY DISCOVERY
JP2023552397A (ja) 可変重鎖のみのライブラリ、その調製方法、及びその使用
Tiller Synthetic Antibodies